Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

JOHNSON & JOHNSON

(JNJ)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

CDC data: Moderna vaccine has edge in preventing COVID-19 hospitalizations

09/17/2021 | 01:21pm EDT

The Moderna COVID-19 vaccine is slightly more effective at preventing serious illness from the virus than its counterpart from Pfizer-BioNTech, according to data released Friday by the Centers for Disease Control and Prevention.

However, both two-dose vaccines, which have similar formulations, are better at reducing the risk for hospitalization due to coronavirus infection than the one-dose Johnson & Johnson shot, the data showed.

The Moderna vaccine lowers an infected person's risk for hospitalization -- or serious illness -- by 93%, starting two weeks after the second dose, the CDC researchers said.

The protection against serious illness created by the vaccine remains above 90% for at least four months, they said.

Meanwhile, the Pfizer-BioNTech vaccined reduces hospitalization risk by 88% among the fully vaccinated, but this protection drops to 77% four months later.

The one-dose Johnson & Johnson vaccine is 71% effective at lowering risk for hospitalization, the CDC said.

"Two-dose regimens of the Moderna and Pfizer-BioNTech mRNA vaccines provided a high level of protection against COVID-19 hospitalizations," the agency researchers wrote.

However, the Johnson & Johnson vaccine "had somewhat lower vaccine effectiveness," they said.

The findings are based on an evaluation of antibody levels among roughly 4,500 adults fully vaccinated against COVID-19, and a comparison of hospitalization rates among those inoculated and about 2,400 unvaccinated adults.

Antibodies are cells produced by the immune system to fight off viruses, and the vaccines are designed to boost anti-coronavirus antibody levels.

The new data includes vaccination and hospitalization data from March 11 to Aug. 15, which coincides with the rise of the more contagious Delta variant in the United States.

Last week, data from the CDC indicated that fully vaccinated people are more than 10 times less likely to be hospitalized due to COVID-19 and more than 10 times less likely to die from the disease.

Separately, studies in Israel found that the Pfizer-BioNTech shot offered up to 97% protection against infection and serious illness.

However, these studies involved the Alpha, or British, variant as opposed to the Delta variant, which is believed to have originated in India.

"These real-world data suggest some variation in levels of protection by vaccine," the CDC researchers said of their new data.

However, "all FDA-approved or authorized COVID-19 vaccines provide substantial protection against COVID-19 hospitalization," they said.

Copyright 2021 United Press International, Inc. (UPI). Any reproduction, republication, redistribution and/or modification of any UPI content is expressly prohibited without UPI's prior written consent., source Health News - Business

Stocks mentioned in the article
ChangeLast1st jan.
JOHNSON & JOHNSON 1.02% 165.75 Delayed Quote.5.32%
MODERNA, INC. -1.09% 345.74 Delayed Quote.230.95%
All news about JOHNSON & JOHNSON
12:36pJohnson & Johnson Statement on Texas Opioid Settlement Agreement
PU
11:01aProtagonist Therapeutics Gets $7.5 Million Milestone Payment from Johnson & Johnson's J..
MT
04:53aNew Analyses Suggest Favorable Results for STELARA (ustekinumab) When Used as a First-L..
AQ
10/25Pfizer, Moderna and J&J Booster Shots Now Available at Walmart and Sam's Club Pharmacie..
AQ
10/25MODERNA : Walgreens Now Offering Moderna and Johnson & Johnson COVID-19 Vaccine Booster Sh..
AQ
10/25JOHNSON & JOHNSON : New Analyses Suggest Favorable Results for STELARA« (ustekinumab) When..
PU
10/25The Janssen Pharmaceutical Companies of Johnson & Johnson announces New Analyses Sugges..
CI
10/22Walgreens Starts Offering Moderna, Johnson & Johnson COVID-19 Booster Shots
MT
10/22CDC approves Moderna, J&J COVID-19 boosters, mixing and matching doses
AQ
10/22MODERNA : CDC Endorses Booster Doses of Moderna, J&N COVID-19 Vaccines
MT
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Financials (USD)
Sales 2021 94 279 M - -
Net income 2021 22 540 M - -
Net cash 2021 924 M - -
P/E ratio 2021 20,0x
Yield 2021 2,52%
Capitalization 436 B 436 B -
EV / Sales 2021 4,62x
EV / Sales 2022 4,33x
Nbr of Employees 134 500
Free-Float 84,3%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | MarketScreener
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Last Close Price 165,75 $
Average target price 185,94 $
Spread / Average Target 12,2%
EPS Revisions
Managers and Directors
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Paulus Stoffels Chief Scientific Officer
James D. Swanson Global Chief Information Officer & Executive VP
Charles O. Prince Independent Director
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON5.32%431 938
ROCHE HOLDING AG15.61%338 364
NOVO NORDISK A/S59.69%243 351
PFIZER, INC.17.22%241 929
ELI LILLY AND COMPANY47.15%222 158
MERCK & CO., INC.-0.17%206 712